AIIMS chief Dr Randeep Guleria says vaccines will be effective against the B1.617 but may have a reduced efficacy. Evidence suggests that reinfection is possible with the new variant, even though the current data is low. Dr Guleria adds that vaccines may have to tweaked in the future to respond to variant strains.